medi3726
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2017 (NCT02991911)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Monomethylauristatin F
Oral
No
Parenteral
No
Topical
No
Also known as
- medi3726
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02991911 | Phase 1 | Jan 6, 2017 | MedImmune, Sponsor GmbH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 1 | 1 | 1 | 2017 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1